Some patients with r/r non-Hodgkin lymphoma (NHL) treated with pembrolizumab after failure of anti-CD19 CAR T cells demonstrated a subsequent CAR T cell re-expansion [76]. Here, CD19 is linked to non-Hodgkin lymphoma.